A Plus Biotechnology Co., Ltd. (TPE:6918)
Taiwan · Delayed Price · Currency is TWD 74.50
+0.50 (0.68%)
Aug 26, 2026, 1:30 PM CST
A Plus Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 887.93 | 835.89 | 769.59 | 675.05 | 615.48 | 541.85 | |
Revenue Growth | 8.94% | 8.62% | 14.01% | 9.68% | 13.59% | 7.66% |
Cost of Revenue | 295.02 | 262.43 | 234.81 | 214.37 | 241.57 | 195.46 |
Gross Profit | 592.91 | 573.46 | 534.78 | 460.67 | 373.91 | 346.39 |
Selling, General & Admin | 330.36 | 318.06 | 299.15 | 233.43 | 230.3 | 237.16 |
Research & Development | 49.28 | 46.64 | 53.34 | 59.54 | 77 | 63.08 |
Operating Expenses | 379.64 | 364.7 | 352.32 | 293.13 | 306.93 | 299.65 |
Operating Income | 213.27 | 208.76 | 182.46 | 167.54 | 66.98 | 46.74 |
Interest Expense | -2.49 | -2.17 | -2.19 | -2.69 | -2.66 | -2.2 |
Interest & Investment Income | 4.24 | 3.79 | 2.27 | 1.71 | 0.83 | 0.42 |
Earnings From Equity Investments | 12.32 | 3.66 | - | - | - | - |
Currency Exchange Gain (Loss) | 1.6 | 1.6 | 1.68 | 0.03 | - | - |
Other Non Operating Income (Expenses) | 5.62 | 0.47 | 3.35 | -163.59 | 2.96 | 1.1 |
EBT Excluding Unusual Items | 234.56 | 216.12 | 187.57 | 3 | 68.11 | 46.06 |
Gain (Loss) on Sale of Assets | -0 | -0 | -0.01 | - | - | - |
Other Unusual Items | 0.02 | 0.02 | - | 0.04 | - | - |
Pretax Income | 234.58 | 216.14 | 187.56 | 3.04 | 68.11 | 46.06 |
Income Tax Expense | 48.34 | 46.6 | 36.5 | 14.34 | 22.41 | 10.43 |
Earnings From Continuing Operations | 186.23 | 169.54 | 151.06 | -11.31 | 45.7 | 35.63 |
Minority Interest in Earnings | -0.44 | -0.16 | - | - | - | -2.69 |
Net Income | 185.79 | 169.38 | 151.06 | -11.31 | 45.7 | 32.94 |
Net Income to Common | 185.79 | 169.38 | 151.06 | -11.31 | 45.7 | 32.94 |
Net Income Growth | 12.16% | 12.13% | - | - | 38.75% | -8.66% |
Shares Outstanding (Basic) | 34 | 33 | 30 | 30 | 30 | 29 |
Shares Outstanding (Diluted) | 34 | 33 | 30 | 30 | 30 | 29 |
Shares Change | 11.74% | 8.36% | 0.37% | -0.71% | 5.45% | 0.95% |
EPS (Basic) | 5.41 | 5.16 | 4.99 | -0.37 | 1.50 | 1.15 |
EPS (Diluted) | 5.40 | 5.15 | 4.97 | -0.37 | 1.50 | 1.14 |
EPS Growth | 0.50% | 3.62% | - | - | 31.58% | -9.52% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 32.15 | 144.79 | 152.09 | 149.72 | 25.52 | -168.55 |
Free Cash Flow Per Share | 0.93 | 4.40 | 5.01 | 4.95 | 0.84 | -5.83 |
Dividend Per Share | - | 5.000 | 4.000 | 2.700 | 0.700 | - |
Dividend Growth | - | 25.00% | 48.15% | 285.71% | - | - |
Gross Margin | 66.77% | 68.60% | 69.49% | 68.24% | 60.75% | 63.93% |
Operating Margin | 24.02% | 24.98% | 23.71% | 24.82% | 10.88% | 8.63% |
Profit Margin | 20.92% | 20.26% | 19.63% | -1.68% | 7.43% | 6.08% |
Free Cash Flow Margin | 3.62% | 17.32% | 19.76% | 22.18% | 4.15% | -31.11% |
EBITDA | 231.31 | 224.9 | 197.32 | 181.35 | 91.84 | 68.17 |
EBITDA Margin | 26.05% | 26.91% | 25.64% | 26.86% | 14.92% | 12.58% |
D&A For EBITDA | 18.04 | 16.14 | 14.86 | 13.81 | 24.86 | 21.43 |
EBIT | 213.27 | 208.76 | 182.46 | 167.54 | 66.98 | 46.74 |
EBIT Margin | 24.02% | 24.98% | 23.71% | 24.82% | 10.88% | 8.63% |
Effective Tax Rate | 20.61% | 21.56% | 19.46% | 472.12% | 32.90% | 22.64% |